Prodrugs for antibody- and gene-directed enzyme prodrug therapies (ADEPT and GDEPT)

Authors
Niculescu-Duvaz, I Friedlos, F Niculescu-Duvaz, D Davies, L Springer, CJ
Citation
I. Niculescu-duvaz et al., Prodrugs for antibody- and gene-directed enzyme prodrug therapies (ADEPT and GDEPT), ANTI-CAN DR, 14(6), 1999, pp. 517-538
Citations number
89
Categorie Soggetti
Onconogenesis & Cancer Research
Journal title
ANTI-CANCER DRUG DESIGN
ISSN journal
02669536 → ACNP
Volume
14
Issue
6
Year of publication
1999
Pages
517 - 538
Database
ISI
SICI code
0266-9536(199912)14:6<517:PFAAGE>2.0.ZU;2-H
Abstract
Antibody- and gene-directed enzyme prodrug therapy are two-step targeting s trategies designed to improve the selectivity of antitumour agents. The app roaches are based on the activation of specially designed prodrugs by antib ody-enzyme conjugates targeted to tumour-associated antigens (ADEPT) or by enzymes expressed by exogenous genes in tumour cells (GDEPT). Herein the de sign, synthesis, physico-chemical and biological properties, kinetics and c linical trials of the prodrugs and the enzymes carboxypeptidase G2 and nitr oreductase are reviewed for ADEPT and GDEPT.